JNJJanssen Research & Development, LLCRunning, no new patients
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
Prostatic Neoplasms
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2
4 insiders sold shares within a month
Since Aug 17, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 2,517 (final count)
- Started
- Jun 11, 2019
- Main results expected
- Dec 1, 2026
- Fully finished
- Oct 13, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Percentage of Participants with Pathologic complete response (pCR)
Measured over: Approximately 4 years
Metastasis-Free Survival (MFS)
Measured over: Up to 7 years and 5 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2, since 2026-08-17, fades (half-life)
Raw record changes
- none yet
Trial ID NCT03767244 · record last updated 2026-11-03 · checked 2026-11-09 15:47 UTC